PPP1R13B and acute myeloid leukemia: Overall survival data were available for the AML cohort of the TCGA repository – which reveals a prognostic advantage for patients harboring high PPP1R13B expression levels (Fig. 2D/E), with a median OS of 26.4 months vs. 19.2 months of the PPP1R13Blow expressors - whereas formal significance was borderline not met due to the small numbers of patients in the cohorts.